Heron Therapeutics traded at $2.88 this Tuesday July 5th, increasing $0.16 or 5.70 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics gained 4.93 percent. Over the last 12 months, its price fell by 80.06 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 2.65 by the end of this quarter and at 2.44 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.88
Daily Change
5.70%
Yearly
-80.06%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,825.00 0 0% -44.52%
ALKERMES 31.27 0.74 2.42% 22.34%
Alnylam Pharmaceuticals 149.70 1.45 0.97% -14.16%
Amarin 1.57 0.13 9.18% -62.92%
Anika Therapeutics 22.72 0.21 0.93% -47.53%
ANI Pharmaceuticals 31.57 0.04 0.11% -6.07%
Arrowhead Research 38.58 2.62 7.29% -38.83%
Emergent BioSolutions 32.76 0.93 2.92% -46.88%
Endo International 0.54 -0.03 -4.56% -87.66%
Esperion Therapeutics 6.87 0.42 6.51% -65.41%
GlaxoSmithKline 1,786.60 -16.00 -0.89% 24.57%
Heron Therapeutics 2.88 0.16 5.70% -80.06%
Immunogen 4.81 0.20 4.23% -23.12%
Insmed 20.70 -0.20 -0.93% -26.25%
Jazz Pharmaceuticals 156.99 -1.59 -1.00% -14.18%
Ligand Pharmaceuticals 94.12 3.54 3.91% -26.95%
Merck & Co 92.41 -0.01 -0.01% 18.31%
Neurocrine Biosciences 98.07 -1.18 -1.19% 0.64%
Nektar Therapeutics 3.85 0.10 2.53% -77.26%
Omeros 3.21 -1.43 -30.82% -78.25%
Pacira 57.78 -0.07 -0.12% 0.24%
Ultragenyx Pharmaceutical 64.16 1.51 2.41% -29.82%
Regeneron Pharmaceuticals 595.00 -0.40 -0.07% 2.19%
Roche Holding 319.00 -3.60 -1.12% -9.76%
Sangamo BioSciences 4.55 0.27 6.31% -59.56%
Surmodics 38.24 0.42 1.11% -28.58%
Teva Pharmaceutical Industries 7.67 -0.22 -2.79% -20.19%
Veracyte 22.82 1.72 8.17% -42.93%
Vertex Pharmaceuticals 288.27 0.95 0.33% 44.10%

Indexes Price Day Year
USND 11264 135.74 1.22% -23.19%
US2000 1728 -0.09 -0.01% -24.04%

Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.